Validating the Translational Utility of the Taconic Diet-Induced Obese (DIO) B6 Mouse Model:
Using semaglutide and tirzepatide as benchmark incretin therapies
Benchmark incretin therapies demonstrate robust efficacy across metabolic, biochemical, and functional endpoints in Taconic’s DIO B6 model. The rapid evolution of obesity therapeutics continues to raise the bar for preclinical model selection. Researchers increasingly require obesity models that not only develop clinically relevant metabolic dysfunction, but also demonstrate predictable responses to therapies with established clinical efficacy.
Developed in collaboration with Transpharmation.
Background
Successful obesity drug discovery depends on models that reproduce key features of human metabolic disease while maintaining sensitivity to pharmacologic intervention.
Benchmark compounds such as semaglutide and tirzepatide provide an opportunity to evaluate whether a model can detect therapeutic effects across multiple domains of disease biology. Demonstrating expected responses to these clinically validated agents increases confidence that efficacy signals generated in the model are biologically meaningful and relevant to human obesity research.
Study Overview and Endpoints
Male C57BL/6NTac mice were maintained on either standard chow or a 60% kcal high-fat diet (Research Diets D12492). Following 13 weeks of diet conditioning, DIO animals were treated daily with vehicle, semaglutide (60 µg/kg), or tirzepatide (10 nmol/kg).
Figure 1. Study design: cohorts, dosing, and endpoint shcedule. n=10 per cohort.
Key Endpoints
Body weight and body composition
Oral Glucose Tolerance Test (OGTT) and Insulin Tolerance Test (ITT)
Clinical biochemistry
Grip strength and locomotor activity
Y-maze behavioral assessment
Tissue collection and endpoint analysis
The DIO Model Established a Robust Metabolic Disease Phenotype
Prior to treatment initiation, DIO animals developed hallmark characteristics of obesity-associated metabolic dysfunction: increased body fat, impaired glucose tolerance, reduced insulin sensitivity, and elevated total cholesterol.
Notably, cholesterol rather than circulating triglycerides emerged as the dominant dyslipidemic feature in this cohort.
Key Takeaway
At baseline, DIO B6 mice developed measurable obesity, glucse dysregulation, insulin resistance, and hypercholesterolemia.
Figure 2A. Baseline body composition by Time-Domain Nuclear Magnetic Resonance (TD-NMR).
The TD-NMR assessment of body composition demonstrates a markedly higher percentage of body fat in the DIO mouse model compared with chow-fed mice.
Figure 2B. Baseline fasting glucose, OGTT, and ITT.
Data are expressed as mean ± SEM. n=10-30 per group. Mixed-effects analysis followed by Fisher’s LSD test/ Student’s t-test or Mann-Whitney U test .
Figure 3. Baseline clinical biochemistry: glucose, total cholesterol, and triglycerides.
Figure 3 (Cont.) Extended baseline clinical biochemistry.
Semaglutide and Tirzepatide Reduced Body Weight and Adiposity
Both incretin therapies induced substantial reductions in body weight and adiposity compared with DIO vehicle controls. Treatment produced significant changes in body weight, body-weight change, and body-fat percentage.
These responses are consistent with the expected pharmacology of GLP-1 receptor agonism and dual GIP/GLP-1 receptor agonism, demonstrating that the model is sensitive to benchmark obesity therapies.
Key Takeaway
The DIO B6 model reliably detected treatment-induced changes in body weight and adiposity
In Vivo Efficacy of Tirzepatide & Semaglutide in Male DIO Mice
Figure 4. Body trajectory, body-weight change, and TD-NMR body fat.
Body weight: statistically significant differences between DIO + vehicle vs DIO + Semaglutide are marked with asterisks (*p<0.05; **p<0.01; ***p<0.001; ****p<0.0001); DIO + vehicle vs DIO + Tirzepatide with hash symbols (#p<0.05; ##p<0.01; ###p<0.001; ####p<0.0001); DIO + Semaglutide vs DIO + Tirzepatide (& p<0.05). Mean ± SEM, n=9–10 per group. Mixed-effects analysis followed by Fisher’s LSD test.
Body weight change and TD-NMR: mean ± SEM, n=9–10 per group. One-way ANOVA followed by Fisher’s LSD test.
Therapeutic Intervention Improved Glucose Homeostasis
In addition to effects on body weight, both semaglutide and tirzepatide improved glycemic control. Treatment was associated with improved oral glucose tolerance, enhanced insulin sensitivity, and lower fasting glucose measurements.
The data show that obesity-associated metabolic abnormalities in the model remain responsive to therapeutically meaningful intervention.
Key Takeaway
The DIO B6 model captured expected improvements in glucose regulation and insulin responsiveness.
Oral Glucose Tolerance Test
Figure 5A. OGTT curve, AUC, and baseline glucose (6h fasting).
Insulin Tolerance Test
Figure 5B. ITT curve, AUC, and baseline glucose (4h fasting).
Data are expressed as mean ± SEM. n=9-10 per group. DIO + vehicle vs DIO + Semaglutide groups, marked with asterisks (**p<0.01; ***p<0.001; ****p<0.0001); DIO + vehicle vs DIO + Tirzepatide groups, marked with hash symbol (###p< 0.001; ####p< 0.0001). Two way Anova, followed by uncorrected Fisher’s LSD.
Treatment Effects Extended Beyond Weight Loss
Clinical biochemistry revealed treatment-associated changes across metabolic and tissue-health markers. Relative to DIO vehicle controls, semaglutide and tirzepatide reduced serum glucose, total cholesterol, ALT, LDH, and CK.
Both DIO vehicle and treated groups showed increased DGGR lipase and α-amylase activities, indicating altered pancreatic enzyme activity.
Key Takeaway
Weight reduction in the DIO B6 model was accompanied by changes across multiple serum chemistry measures.
Clinical Biochemistry—After Treatment
Figure 6. Clinical biochemistry after treatment.
Mean ± SEM, n=6–9 per group. Normality was assessed with the Shapiro-Wilk test; ordinary one-way ANOVA or Mann-Whitney U test was used as appropriate. All statistically significant differences are indicated on the graphs.
Tirzepatide and semaglutide treatment effectively restored serum glucose levels in DIO mice to those comparable with chow-fed controls. Compared with DIO vehicle controls, tirzepatide and semaglutide treatment significantly reduced total cholesterol levels.
Non-fasting serum triglyceride levels showed a trend toward increased levels in DIO mice compared with chow-fed controls. Following treatment with tirzepatide or semaglutide, triglyceride levels were reduced toward those observed in the chow control group.
Both treatments significantly reduced serum ALT and LDH levels compared with DIO vehicle controls, suggesting an improvement in hepatic and overall metabolic health. Tirzepatide and semaglutide treatment significantly reduced serum CK levels compared with DIO vehicle controls, suggesting a reduction in muscle stress or tissue injury.
Both DIO and treatment with tirzepatide or semaglutide were associated with increased serum DGGR lipase and α-amylase activities, indicating alterations in pancreatic enzyme activity.
Treatment Effects Extended Beyond Weight Loss
Diet-induced obesity was associated with lower locomotor activity and reduced grip strength at baseline. Both treatments increased grip strength relative to DIO vehicle controls, although strength did not fully return to chow-control levels. Tirzepatide appeared to increase locomotor activity compared with DIO vehicle controls.
Key Takeaway
Functional endpoints may broaden study interpretation when they are prespecified and mechanistically relevant.
Locomotor Activity
Locomotor activity was assessed in a 10-minute open-field test under dim lighting conditions (30 lux), with data recorded as video files using the ANY-maze software.
Grip Strength
Grip strength was measured on the forelimbs using BIOSEB’s Grip Strength Test and expressed as gram-force (gf)/g body weight, calculated as the average of 3–5 trials.
Figure 7. Locomotor activity and grip strength, baseline and after treatment.
Data are expressed as mean ± SEM, n=9–10 per group. Normality was assessed with the Shapiro-Wilk test; t-test or ordinary one-way ANOVA was used as appropriate.
No Significant Treatment Effects on Spatial Working-Memory Performance
In the Y-maze, spontaneous alternation did not differ significantly between DIO mice and chow-fed controls, providing no evidence of a spatial working-memory deficit in this assay. At baseline, DIO mice made fewer total arm entries, consistent with lower exploratory activity. Neither semaglutide nor tirzepatide significantly altered spontaneous alternation or total arm entries following treatment.
Baseline
Figure 8A. Mean ± SEM, n=10–30 per group. Unpaired Welch’s t-test.
After Treatment
Figure 8B. Mean ± SEM, n=9–10 per group. One-way ANOVA followed by Fisher’s LSD test.
DIO mice did not exhibit significant differences in Y-maze performance compared with chow-fed controls, indicating no evident impairment in spatial working memory. However, DIO mice showed reduced overall activity at baseline, as reflected by a lower number of total arm entries. Treatment with tirzepatide or semaglutide did not produce significant changes in Y-maze performance or overall activity, suggesting that neither therapy had a measurable effect on the parameters assessed in this test.
Applications for Obesity Drug Development
Discussion
Scientific Perspective
A model's ability to reproduce expected responses to clinically established therapies provides a practical benchmark for pharmacologic responsiveness.
One challenge in obesity drug discovery is distinguishing true therapeutic activity from model-specific artifacts.
In this study, semaglutide and tirzepatide produced expected improvements across body weight, adiposity, glucose control, cholesterol, clinical chemistry, and selected functional endpoints. Collectively, these findings support the Taconic DIO B6 model as a pharmacologically responsive platform for evaluating current and next-generation obesity therapeutics.
About the Taconic DIO Model
Evaluate Anti-obesity Therapies in a Pharmacologically Responsive DIO Model
Featured Cardiometabolic Disease Resources
Get In Touch
Connect with Taconic’s scientific team to discuss model selection, study design, and available research support.
If you need immediate assistance, please contact Customer Service:
Taconic Corporate Offices
Email: info@taconic.com
Phone: +1 (518) 697-3900
273 Hover Ave., Germantown, NY 12526
North American Customer Service
Email: info@taconic.com
Phone:
+1 (518) 697-3915
Toll-free:
+1 (888) 822-6642
Hours:
(Monday - Friday): 7 a.m. - 6 p.m. ET
European Customer Service
Email: info@taconic.com
Phone (Europe and Denmark):
+45 70 23 04 05
Phone (Germany):
+49 214 50 68 023
Hours: (Monday - Friday):
7 a.m. - 5 p.m. CET